NehaMehtaMehta-ShahMD

Physician

Dr. Mehta-Shah is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Office
4921 Parkview Pl
# Dv
Saint Louis, MO 63110
Phone+1 800-647-2098

Fax+1 314-362-3192

Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2013 - 2016
New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 2010 - 2012
Northwestern University The Feinberg School of MedicineClass of 2009

Minimal Residual Disease in Peripheral T-cell Lymphoma Start of enrollment: 2017 Jul 31
Completed
Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma Start of enrollment: 2021 Jul 30
Recruiting
Phase 2
Roles: Principal Investigator, Contact, Study Chair
Acalabrutinib and Durvalumab in Primary and Secondary Central Nervous System Lymphoma Start of enrollment: 2021 Apr 29
Recruiting
Phase 1
Roles: Principal Investigator, Contact
Tulmimetostat (CPI-0209) in Patients With Mycosis Fungoides and Sézary Syndrome Start of enrollment: 2024 Jan 09
Recruiting
Phase 1
Roles: Principal Investigator, Contact
Polatuzumab Vedotin (Pola) Plus Rituximab (R) in Patients With Post-transplant Lymphoproliferative Disorder (PTLD) Start of enrollment: 2023 Oct 04
Recruiting
Phase 1, Phase 2
Roles: Principal Investigator, Contact
Join now to see all

PubMed

6 citations
Alopecia areata after mogamulizumab treatment
Neel S. Raval, Nora A. Alexander, Karlee De Monnin, Christine C. Yokoyama, Neha Mehta-Shah
JAAD Case Reports. 2021-11-01
An Update on the Current Genomic Landscape of Breast Implant-Associated Anaplastic Large Cell Lymphoma.
Sean Harrop, Neha Mehta-Shah, Criselle D'Souza, Ella R. Thompson, Anand K. Deva
Cancers. 2021-09-30
18 citations
Romidepsin and lenalidomide-based regimens have efficacy in relapsed/refractory lymphoma: Combined analysis of two phase I studies with expansion cohorts
Neha Mehta-Shah, Matthew A. Lunning, Alison J. Moskowitz, Adam M. Boruchov, Jia Ruan
American Journal of Hematology. 2021-07-12

Abstracts/Posters

Characteristics, Treatment Patterns, and Outcomes in Primary Cutaneous Gamma Delta T Cell Lymphoma (PCGDTCL): A Real World Multi-Institutional Analysis of a Rare Malig...
Neha Mehta-Shah, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Dose Optimization of Duvelisib in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma from the Phase 2 Primo Trial: Selection of Regimen for the Dose-Expan...
Neha Mehta-Shah, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019

Lectures

Aggressive Non-Hodgkin Lymphomas: It's Getting Personal
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Romidepsin in Combination with Gemcitabine, Oxaliplatin, and Dexamethasone Shows Durable Responses in Aggressive Lymphomas
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Rituximab/Bendamustine and Rituximab/Cytarabine (RB/RC) Induction Chemotherapy for Transplant-Eligible Patients with Mantle Cell Lymphoma: A Pooled Analysis of Two Pha...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018